TY - JOUR
T1 - Association of mir-21-5p, mir-122-5p, and mir-320a-3p with 90-day mortality in cardiogenic shock
AU - Hänninen, Mikko
AU - Jäntti, Toni
AU - Tolppanen, Heli
AU - Segersvärd, Heli
AU - Tarvasmäki, Tuukka
AU - Lassus, Johan
AU - Vausort, Mélanie
AU - Devaux, Yvan
AU - Sionis, Alessandro
AU - Tikkanen, Ilkka
AU - Harjola, Veli Pekka
AU - Lakkisto, Päivi
N1 - Funding Information:
This work was supported by grants from the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, Aarne Koskelo Foundation, Finnish Foundation for Laboratory Medicine, Finska L?kares?llskapet, the Liv och H?lsa Foundation, the Finnish Society of Clinical Chemistry, and Finnish state funding for university-level research. The CardShock study investigators in all participating hospitals. The CardShock steering committee: Veli-Pekka Harjola, Marek Banaszewski, Lars K?ber, Johan Lassus, Alexandre Mebazaa, Marco Metra, John Parissis, Jose Silva-Cardoso, Alessandro Sionis, Salvatore Di Somma, and Jindrich Spinar. List of investigators: Athens: Katerina Koniari, Astrinos Voumvourakis, Apostolos Karavidas; Barcelona: Jordi Sans-Rosello, Montserrat Vila, Albert Duran-Cambra; Brescia: Marco Metra, Michela Bulgari, Valentina Lazzarini; Brno: Jiri Parenica, Roman Stipal, Ondrej Ludka, Marie Palsuva, Eva Ganovska, Petr Kubena; Copenhagen: Matias G. Lindholm, Christian Hassager; Helsinki: Tom B?cklund, Raija Jurkko, Kristiina J?rvinen, Tuomo Nieminen, Kari Pulkki, Leena Soininen, Reijo Sund, Ilkka Tierala, Jukka Tolonen, Marjut Varpula, Tuomas Korva, Mervi Pietil?, Anne Pitk?l?; Rome: Rossella Marino; Porto: Alexandra Sousa, Carla Sousa, Mariana Paiva, In?s Rangel, Rui Almeida, Teresa Pinho, Maria J?lia Maciel; Warsaw: Janina Stepinska, Anna Skrobisz, Piotr G?ral. The study was conducted in collaboration with the Global REsearch on Acute Conditions Team (GREAT) network. The expert technical assistance of Katariina Immonen is gratefully acknowledged. Open access funding provided by University of Helsinki.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - Cardiogenic shock (CS) is a life-threatening emergency. New biomarkers are needed in order to detect patients at greater risk of adverse outcome. Our aim was to assess the characteristics of miR-21-5p, miR-122-5p, and miR-320a-3p in CS and evaluate the value of their expression levels in risk prediction. Circulating levels of miR-21-5p, miR-122-5p, and miR-320a-3p were measured from serial plasma samples of 179 patients during the first 5–10 days after detection of CS, derived from the CardShock study. Acute coronary syndrome was the most common cause (80%) of CS. Baseline (0 h) levels of miR-21-5p, miR-122-5p, and miR-320a-3p were all significantly elevated in nonsurvivors compared to survivors (p < 0.05 for all). Above median levels at 0h of each miRNA were each significantly associated with higher lactate and alanine aminotransferase levels and decreased glomerular filtration rates. After adjusting the multivariate regression analysis with established CS risk factors, miR-21-5p and miR-320a-3p levels above median at 0 h were independently associated with 90-day all-cause mortality (adjusted hazard ratio 1.8 (95% confidence interval 1.1–3.0), p = 0.018; adjusted hazard ratio 1.9 (95% confidence interval 1.2–3.2), p = 0.009, respectively). In conclusion, circulating plasma levels of miR-21-5p, miR-122-5p, and miR-320a-3p at baseline were all elevated in nonsurvivors of CS and associated with markers of hypoperfusion. Above median levels of miR-21-5p and miR-320a-3p at baseline appear to independently predict 90-day all-cause mortality. This indicates the potential of miRNAs as biomarkers for risk assessment in cardiogenic shock.
AB - Cardiogenic shock (CS) is a life-threatening emergency. New biomarkers are needed in order to detect patients at greater risk of adverse outcome. Our aim was to assess the characteristics of miR-21-5p, miR-122-5p, and miR-320a-3p in CS and evaluate the value of their expression levels in risk prediction. Circulating levels of miR-21-5p, miR-122-5p, and miR-320a-3p were measured from serial plasma samples of 179 patients during the first 5–10 days after detection of CS, derived from the CardShock study. Acute coronary syndrome was the most common cause (80%) of CS. Baseline (0 h) levels of miR-21-5p, miR-122-5p, and miR-320a-3p were all significantly elevated in nonsurvivors compared to survivors (p < 0.05 for all). Above median levels at 0h of each miRNA were each significantly associated with higher lactate and alanine aminotransferase levels and decreased glomerular filtration rates. After adjusting the multivariate regression analysis with established CS risk factors, miR-21-5p and miR-320a-3p levels above median at 0 h were independently associated with 90-day all-cause mortality (adjusted hazard ratio 1.8 (95% confidence interval 1.1–3.0), p = 0.018; adjusted hazard ratio 1.9 (95% confidence interval 1.2–3.2), p = 0.009, respectively). In conclusion, circulating plasma levels of miR-21-5p, miR-122-5p, and miR-320a-3p at baseline were all elevated in nonsurvivors of CS and associated with markers of hypoperfusion. Above median levels of miR-21-5p and miR-320a-3p at baseline appear to independently predict 90-day all-cause mortality. This indicates the potential of miRNAs as biomarkers for risk assessment in cardiogenic shock.
KW - Cardiogenic shock
KW - MicroRNA
KW - Mortality
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85094100228&partnerID=8YFLogxK
U2 - 10.3390/ijms21217925
DO - 10.3390/ijms21217925
M3 - Article
C2 - 33114482
AN - SCOPUS:85094100228
SN - 1661-6596
VL - 21
SP - 1
EP - 12
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 21
M1 - 7925
ER -